Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies - (Tables)

v3.20.1
Significant Accounting Policies - (Tables)
12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Disaggregation of Revenue
The following table presents net revenues disaggregated by type:

 
 
Year Ended December 31,
 
 
2019
 
2018
Prescription drugs
 
$
6,650,351

 
$
6,572,322

Sales force revenue
 

 
456,056

License and other revenue
 
100,000

 

Total revenues, net from continuing operations
 
$
6,750,351

 
$7,028,378